Zeta Cd3 Antibody. Zeta’s recombinant house antibody recognizes C3d (Complement component C3), which plays a central role in the activation of complement system. C3d activation is required for both classical and alternative complement activation pathways. C3d deposition in the renal transplant PTCs (peritubular capillaries) is indicative of AR (acute rejection)with subsequent high probability of graft loss. The C3d antibody, combined with anti-C4d, can be utilized as a tool for diagnosis of AR and warrant prompt and aggressive anti-rejection treatment. It was shown that a C3d antibody labeled the epidermal basement membrane in 97% cases of bullous pemphigoid, with none of the normal controls demonstrating such findings. 27% cases of pemphigus vulgaris demonstrate intercellular C3d deposition. Therefore, C3d immunohistochemistry is a helpful adjunct in the diagnosis of bullous pemphigoid(and perhaps pemphigus vulgaris), especially in the cases in which only formalin-fixed, paraffin embedded tissue is available for analysis.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.